Hedley Douglas, Ogilvie Lesley, Springer Caroline
Institute of Cancer Research Haddow Laboratories, 15, Cotswold Road, Sutton, Surrey, UK.
Nat Rev Cancer. 2007 Nov;7(11):870-9. doi: 10.1038/nrc2247.
Gene-directed enzyme-prodrug therapy (GDEPT) aims to improve the therapeutic ratio (benefit versus toxic side-effects) of cancer chemotherapy. A gene encoding a 'suicide' enzyme is introduced into the tumour to convert a subsequently administered non-toxic prodrug into an active drug selectively in the tumour, but not in normal tissues. Significant effects can now be achieved in vitro and in targeted experimental models, and GDEPT therapies are entering the clinic. Our group has developed a GDEPT system that uses the bacterial enzyme carboxypeptidase G2 to convert nitrogen mustard prodrugs into potent DNA crosslinking agents, and a clinical trial of this system is pending.
基因导向酶-前体药物疗法（GDEPT）旨在提高癌症化疗的治疗比率（益处与毒副作用之比）。一种编码“自杀”酶的基因被导入肿瘤中，以便将随后给予的无毒前体药物选择性地在肿瘤而非正常组织中转化为活性药物。目前在体外和靶向实验模型中已能取得显著效果，并且GDEPT疗法正在进入临床阶段。我们的团队已开发出一种GDEPT系统，该系统利用细菌酶羧肽酶G2将氮芥前体药物转化为强效的DNA交联剂，此系统的一项临床试验正在筹备中。
Zotero 插件